ストックスクリーナーアプリを入手
5.38
0.37%
-0.02
アフターアワーズ：
5.38
前日終値:
$5.40
開ける：
$5.38
24時間の取引高:
513.11K
Relative Volume:
0.43
時価総額：
$1.21B
収益：
$596.48M
当期純損益:
$123.72M
株価収益率:
9.8104
EPS:
0.5484
ネットキャッシュフロー:
$106.59M
1週間 パフォーマンス:
-1.28%
1か月 パフォーマンス:
-1.47%
6か月 パフォーマンス:
+75.82%
1年 パフォーマンス:
+64.02%
1日の値動き範囲:
$5.365
$5.40
1週間の範囲:
$5.365
$5.48
52週間の値動き範囲:
$2.37
$5.72
Curevac N V Stock (CVAC) Company Profile
CVAC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.38 | 1.22B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-25 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 開始されました | SVB Securities | Outperform |
| 2023-01-19 | アップグレード | UBS | Neutral → Buy |
| 2023-01-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-01-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-06-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Underperform |
| 2021-04-26 | 開始されました | Guggenheim | Neutral |
| 2020-12-10 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 開始されました | BofA Securities | Buy |
| 2020-09-08 | 開始されました | Credit Suisse | Neutral |
| 2020-09-08 | 開始されました | Jefferies | Hold |
すべてを表示
Curevac N V (CVAC) 最新ニュース
CureVac N.V. stock daily chart insightsQuarterly Trade Review & Growth Focused Entry Reports - Newser
How to integrate CureVac N.V. into portfolio analysis toolsBear Alert & Safe Entry Point Identification - Newser
Should you wait for a breakout in CureVac N.V.2025 Key Lessons & Growth Focused Entry Reports - Newser
What Fibonacci levels say about CureVac N.V. reboundMarket Performance Report & Weekly Stock Performance Updates - Newser
Does CureVac N.V. qualify in momentum factor screeningEarnings Recap Summary & Growth Focused Stock Reports - Newser
CureVac N.V. Price Targets Raised After Rebound getLinesFromResByArray error: size == 0 - 더경남뉴스
CureVac N.V. Rebounds From Oversold Zone — Now What getLinesFromResByArray error: size == 0 - 더경남뉴스
What technical models suggest about CureVac N.V.’s comebackQuarterly Profit Report & AI Powered Market Trend Analysis - Newser
CureVac’s Strategic Moves and Financial Highlights in 2025 - TipRanks
MACD Signals Flash Warning for CureVac N.V. StockRisk Management & Long-Term Safe Investment Plans - newsyoung.net
Will CureVac N.V. price bounce be sustainable2025 Big Picture & Entry Point Confirmation Signals - Newser
Is CureVac N.V. stock bottoming outEntry Point & Stepwise Trade Signal Implementation - Newser
Key resistance and support levels for CureVac N.V.2025 Short Interest & Target Return Focused Stock Picks - Newser
Portfolio Update: Can CureVac N.V. deliver consistent EPS growthJuly 2025 Earnings & Technical Pattern Recognition Alerts - theviewers.co.kr
Is CureVac N.V. part of any ETFTrade Entry Report & Fast Momentum Stock Entry Tips - sundaytimes.kr
Is it time to cut losses on CureVac N.V.2025 Key Lessons & Smart Money Movement Tracker - Newser
Is CureVac N.V. forming a breakout patternIndex Update & Real-Time Stock Price Movement Reports - sundaytimes.kr
CureVac NV earnings missed by €0.21, revenue fell short of estimates - Investing.com Australia
CureVac: Despite weak Q2, acquisition remains on track - MarketScreener
CureVac N.V. Volume Confirms Breakout — Analysts BullishDay Trade & Expert Verified Stock Movement Alerts - classian.co.kr
Investors Hope for Bounce in CureVac N.V. After Selloff2025 Market Trends & High Conviction Buy Zone Picks - metal.it
Published on: 2025-08-17 02:22:48 - Newser
What to do if you’re stuck in CureVac N.V.2025 Year in Review & Daily Momentum Trading Reports - Newser
Will breakout in CureVac N.V. lead to full recoveryJuly 2025 Spike Watch & Accurate Buy Signal Alerts - Newser
CureVac Reports Financial Losses in Mid-2025 - MSN
CureVac N.V. Stages Intraday Comeback — Trend Change2025 Institutional Moves & High Accuracy Trade Signal Alerts - 선데이타임즈
Is a relief rally coming for CureVac N.V. holders2025 Market Trends & Fast Entry Momentum Trade Alerts - Newser
How high can CureVac N.V. stock goWeekly Investment Report & Free Risk Controlled Daily Trade Plans - Newser
CureVac's Q2 Pre-Tax Loss Narrows, Revenue Falls - MarketScreener
Earnings Flash (CVAC) CureVac Posts Q2 Revenue 1.2M Euros, vs. FactSet Est of 3.3M Euros - MarketScreener
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates | CVAC Stock News - GuruFocus
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - ACCESS Newswire
$740M Patent Settlement: CureVac Resolves Pfizer Dispute and Agrees to BioNTech Acquisition Deal - Stock Titan
How does CureVac N.V. compare to its peersExit Point & Risk Managed Investment Strategies - thegnnews.com
Is There Enough Volume to Lift CureVac N.V.Weekly Market Report & Free Long-Term Investment Growth Plans - newsyoung.net
CureVac (CVAC) to Release Earnings on Thursday - Defense World
How CureVac N.V. stock performs during market volatilityPrice Forecast Based on AI Analysis - Newser
CureVac NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView
CureVac N.V. (NASDAQ:CVAC) Holdings Raised by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
mRNA Cancer Vaccine Market Is Going to Boom | Major Giants BioNTech, Moderna, CureVac, Gilead Sciences - newstrail.com
Analyzing CureVac (NASDAQ:CVAC) & ARAVIVE (NASDAQ:ARAV) - Defense World
Can CureVac N.V. keep up with sector leadersSmart Money ROI Picks - sisain.net
GSK set to get $500 million from settlement of mRNA lawsuit - The Economic Times
Can a trend reversal in CureVac N.V. lead to recoverySmart Swing Picks with Confirmed Signals - Newser
BioNTech (BNTX) Settles mRNA Patent Dispute with CureVac for US$370 Million - Yahoo Finance
BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal - BioPharma Dive
Drawdown in CureVac N.V. May Be Nearing EndFast Gaining Stock Screener Reports Released - beatles.ru
GSK Secures $370 Million In MRNA Patent Settlement Windfall - Finimize
CureVac Enters Agreements to Resolve mRNA Patent Litigation with Pfizer/BioNTech - Contract Pharma
CureVac announces resolution of patent litigation with Pfizer/BioNTech - Medical Dialogues
Curevac N V (CVAC) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
8.06%
大文字化:
|
ボリューム (24 時間):